ZBH Pengajuan SEC - Zimmer Biomet Holdings, Inc.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

LEI	2P2YLDVPES3BXQ1FRB91
CIK	1136869

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Zimmer Biomet Holdings, Inc.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

September 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 ZIMMER BIOMET H UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com
August 7, 2025	EX-99.1	Zimmer Biomet Announces Second Quarter 2025 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Kristen Cardillo David DeMartino (925) 786-4913 (646) 531-6115 [email protected] [email protected] Kirsten Fallon Zach Weiner (781) 779-5561 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces Second Quarter 2025 Financial Results • Secon
August 7, 2025	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of June 30, 2025 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International, Inc. Delaware Biomet Manufacturing, LLC Ind
August 7, 2025	10-Q	SECURITIES AND EXCHANGE COMMISSION FOR THE QUARTERLY PERIOD ENDED June 30, 2025 June 30, 2025 Page Part I - Financial Information Part II - Other Information Signatures 40 1. Basis of Presentation 2. Significant Accounting Policies ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2025 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation
August 7, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commis
July 14, 2025	EX-99.1	Disclaimer Cautionary Note Regarding Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including any statements EX-99.1 MOVING YOU FORWARD July 14, 2025 ZBH Acquisition of Monogram Technologies Inc. Exhibit 99.1 Disclaimer Cautionary Note Regarding Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including any statements about us; Monogram Technologies Inc. (“Monogram”);
July 14, 2025	EX-99.2	Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions Proposed transaction creates the broadest, most flexible portfolio of orthopedic robotics and navigation technologies to EX-99.2 Exhibit 99.2 Zimmer Biomet: Media Kristen Cardillo 925-786-4913 [email protected] Kirsten Fallon 781-779-5561 [email protected] Investors David DeMartino 646-531-6115 [email protected] Zach Weiner 908-591-6955 [email protected] Monogram Technologies: Media and Investors: Chris Tyson MZ North America Direct 949-4791-8235 [email protected]
July 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 ZIMMER BIOMET HOLDI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commiss
June 30, 2025	EX-10.1	Five-Year Revolving Credit Agreement, dated as of June 27, 2025, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent Exhibit 10.1 EXECUTION VERSION FIVE-YEAR REVOLVING CREDIT AGREEMENT dated as of June 27, 2025, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., MIZUHO BANK, LTD., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SECURIT
June 30, 2025	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commiss
June 30, 2025	EX-10.2	364-Day Revolving Credit Agreement, dated as of June 27, 2025, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent Exhibit 10.2 EXECUTION VERSION 364-DAY REVOLVING CREDIT AGREEMENT dated as of June 27, 2025, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., MIZUHO BANK, LTD., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SECURITIE
June 20, 2025	EX-FILING FEES	Filing Fee Table. Calculation of Filing Fee Tables S-8 ZIMMER BIOMET HOLDINGS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.01 par value per share, 2009 Stock Incentive Plan Other 10,000,000 $ 91.04 $ 910,400,00
June 20, 2025	S-8	As filed with the Securities and Exchange Commission on June 20, 2025 S-8 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No.
June 3, 2025	EX-10.1	Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan, as amended and restated (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed June 3, 2025). Exhibit 10.1 ZIMMER BIOMET HOLDINGS, INC. 2009 STOCK INCENTIVE PLAN (As Amended on May 29, 2025) 1. GENERAL. (a) Establishment of Plan; Merger of Prior Plans. The Zimmer Holdings, Inc. 2009 Stock Incentive Plan (now known as the Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan) (the “Plan”) originally became effective on May 4, 2009 (the “2009 Effective Date”) as a successor to the Zimmer Ho
June 3, 2025	8-K	FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commissi
June 3, 2025	EX-3.1	Certificate of Amendment of Restated Certificate of Incorporation of Zimmer Biomet Holdings, Inc., dated May 29, 2025. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF ZIMMER BIOMET HOLDINGS, INC. Zimmer Biomet Holdings, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. This Certificate of Amendment (the “Certificate of Amendment”) amends the provisions of the Corporation’s Resta
June 3, 2025	EX-3.2	Restated Certificate of Incorporation of Zimmer Biomet Holdings, Inc., dated May 29, 2025. Exhibit 3.2 RESTATED CERTIFICATE OF INCORPORATION OF ZIMMER BIOMET HOLDINGS, INC. The corporation was incorporated under the name “Zodiac Holdings, Inc.” by the filing of its original Certificate of Incorporation with the Secretary of State of Delaware on January 12, 2001 (the “Original Certificate of Incorporation”). The corporation filed a Certificate of Amendment of the Original Certificate of
May 27, 2025	EX-10.5	Employee Non-Disclosure, Trade Secret and Intellectual Property Agreement, dated as of May 24, 2025, by and between Zimmer Biomet Holdings, Inc. and Kevin Thornal. EX-10.5 Exhibit 10.5 EMPLOYEE NON-DISCLOSURE, TRADE SECRET AND INTELLECTUAL PROPERTY AGREEMENT This Employee Non-Disclosure, Trade Secret and Intellectual Property Agreement (“Agreement”) is made and entered into by and between Zimmer Biomet Holdings, Inc., a corporation having its principal headquarters in Warsaw, Indiana, and Kevin Thornal (“Employee”). Recitals A. For purposes of this Agreement
May 27, 2025	EX-99.1	Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Heather Zoumas-Lubeski David DeMartino 445-248-0577 646-531-6115 [email protected] [email protected] Zach Weiner 908-591-6955 [email protected] Zimmer Biomet Appoints Kevin Thornal as Group President, Global Businesses and the Americas (WARSAW, IN) May 27, 2025 — Zimme
May 27, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commissi
May 27, 2025	EX-10.1	Offer Letter, dated as of May 20, 2025, by and between Zimmer Biomet Holdings, Inc. and Kevin Thornal. Exhibit 10.1 Confidential May 20, 2025 Kevin Thornal [*] [*] Dear Kevin, We are pleased to offer you the position of Group President, Global Businesses and the Americas reporting to me. You will be paid a gross annual salary of $850,000 in bi-weekly installments and your salary grade will be a Z02. Your position is exempt, as such, your annual salary is intended to compensate you for all hours
May 23, 2025	EX-1.01	Conflict Minerals Report of Zimmer Biomet Holdings, Inc. Exhibit 1.01 ZIMMER BIOMET HOLDINGS, INC. Conflict Minerals Report For the Reporting Period from January 1, 2024 to December 31, 2024 This Conflict Minerals Report (this “Report”) of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet,” the “Company,” “we,” “our” or “us”) has been prepared pursuant to Rule 13p-1 and Form SD (collectively, the “Rule”) promulgated under the Securities Exchange Act of 1934,
May 23, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 345 East Main Street Warsaw, Indiana 46580 (Address of principal ex
May 5, 2025	EX-10.1	Swiss Employment Agreement by and between Zimmer GmbH and Jehanzeb Noor dated as of February 13, 2025 Exhibit 10.1 Zimmer GmbH Zählerweg 4 CH-6300 Zug Phone +41 (0)58 854 90 00 www.zimmerbiomet.com Employment Agreement between Zimmer GmbH Zählerweg 4, 6300 Zug (hereinafter referred to as "Zimmer") and Mr. Jehanzeb Noor, born on January 7, 1982, American Citizen (hereinafter referred as "Mr. Noor“) will be hired in terms of Art. 319ff. CO ("Agreement"). 1. Hire date, position and work location 1.1
May 5, 2025	EX-10.3	Confidentiality, Non-Competition and Non-Solicitation Agreement dated as of February 14, 2025 by and between Zimmer GmbH and Jehanzeb Noor Exhibit 10.3 Zimmer GmbH Zählerweg 4 CH-6300 Zug Phone +41 (0)58 854 90 00 www.zimmerbiomet.com Confidentiality, Non-Competition, and Non-Solicitation Agreement between Zimmer GmbH Zählerweg 4, 6300 Zug („Employer“) and Mr. Jehanzeb Noor („Employee“) (collectively the "Parties") Recitals (A) For purposes of this Agreement, "Parent" means an entity which is a holding company of or holds a controlli
May 5, 2025	EX-99.1	Zimmer Biomet Announces First Quarter 2025 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 [email protected] [email protected] Zach Weiner (908) 591-6955 [email protected] Zimmer Biomet Announces First Quarter 2025 Financial Results • First quarter net sales of $1.909 billion increased 1.1%
May 5, 2025	10-Q	SECURITIES AND EXCHANGE COMMISSION FOR THE QUARTERLY PERIOD ENDED March 31, 2025 March 31, 2025 Page Part I - Financial Information Part II - Other Information Signatures 37 1. Basis of Presentation 2. Significant Accounting Polici ` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2025 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation
May 5, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commissio
May 5, 2025	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of March 31, 2025 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International, Inc. Delaware Biomet Manufacturing, LLC In
May 5, 2025	EX-10.2	Change in Control Severance Agreement by and between Zimmer GmbH and Jehanzeb Noor effective as of February 13, 2025 Exhibit 10.2 Change in Control Severance Agreement This Change in Control Severance Agreement ("Agreement") is made by and between Zimmer GmbH ("Employer" or "Company" as case may be) and Jehanzeb Noor ("Executive"). Recitals (A) The Company considers it essential to the best interests of its ultimate shareholders to foster the continuous employment of key management personnel. (B) The Company and
April 21, 2025	EX-99.1	Zimmer Biomet Completes Acquisition of Paragon 28 Transaction Further Strengthens Company’s Position in High-Growth Foot and Ankle Segment Exhibit 99.1 Zimmer Biomet: Media Heather Zoumas-Lubeski 445-248-0577 [email protected] Kirsten Fallon 781-779-5562 [email protected] Investors David DeMartino 646-531-6115 [email protected] Zach Weiner 908-591-6955 [email protected] Zimmer Biomet Completes Acquisition of Paragon 28 Transaction Further Strengthens Company’s Position in
April 21, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commis
April 14, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 14, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin
April 2, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☑ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
February 25, 2025	EX-99.1	345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 [email protected] [email protected] Zach Weiner (908) 591-6955 zach.wein Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 [email protected] [email protected] Zach Weiner (908) 591-6955 [email protected] Zimmer Biomet Announces Upcoming Changes to Company’s Board of Directors (WARSAW, IN) February 25, 2025 — Zimmer Biom
February 25, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2024 Commission file number 001-16407 ZIMMER BIOMET HOL I have UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2024 Commission file number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State of Incorporation) (IRS Employer Identification No
February 25, 2025	EX-FILING FEES	Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC.
February 25, 2025	EX-25.1	Statement of Eligibility of Computershare Trust Company, N.A. on Form T-1 for Debt Securities. Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) N
February 25, 2025	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of December 31, 2024 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International, Inc. Delaware Biomet Manufacturing, LLC
February 25, 2025	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com
February 25, 2025	S-3ASR	As filed with the Securities and Exchange Commission on February 25, 2025 Table of Contents As filed with the Securities and Exchange Commission on February 25, 2025 Registration No.
February 25, 2025	EX-19	Zimmer Biomet Holdings, Inc. Stock Trading Policy, effective April 26, 2023 LEGAL 101 Rev. 3 Global Policy STOCK TRADING POLICY Level 1 Non-QMS Document Effective Date: 26 APR 2023 Exhibit 19 PURPOSE Securities laws prohibit individuals from trading in the securities of a company while they are aware of material information about that company that is not generally known or available to the public. Such trading is often referred to as “insider trading.” The purpose of this
February 25, 2025	EX-4.1	Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 Exhibit 4.1 Description of the Registrant’s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 As of December 31, 2024, Zimmer Biomet Holdings, Inc. (the “Company,” “we,” “our” and “us” refer solely to Zimmer Biomet Holdings, Inc.) maintained four classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1
February 19, 2025	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com
February 19, 2025	EX-4.2	Twelfth Supplemental Indenture, dated as of February 19, 2025, between Zimmer Biomet Holdings, Inc. and Computershare Trust Company, N.A., as trustee. EX-4.2 Exhibit 4.2 ZIMMER BIOMET HOLDINGS, INC. $600,000,000 4.700% Notes due 2027 $550,000,000 5.050% Notes due 2030 $600,000,000 5.500% Notes due 2035 TWELFTH SUPPLEMENTAL INDENTURE Dated as of February 19, 2025 to Indenture dated as of November 17, 2009 COMPUTERSHARE TRUST COMPANY, N.A. Trustee Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Application
February 18, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com
February 18, 2025	EX-1.1	Underwriting Agreement, dated as of February 11, 2025, among Zimmer Biomet Holdings, Inc., Goldman Sachs & Co. LLC, Barclays Capital Inc., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and SMBC Nikko Securities America, Inc., as representatives of the several underwriters named in Schedule I thereto. Exhibit 1.1 Execution Version Zimmer Biomet Holdings, Inc. $600,000,000 4.700% Notes due 2027 $550,000,000 5.050% Notes due 2030 $600,000,000 5.500% Notes due 2035 Underwriting Agreement New York, New York February 11, 2025 Goldman Sachs & Co. LLC Barclays Capital Inc. Citigroup Global Markets Inc. Morgan Stanley & Co. LLC SMBC Nikko Securities America, Inc. As representatives of the several under
February 13, 2025	EX-FILING FEES	Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC.
February 13, 2025	424B5	$1,750,000,000 Zimmer Biomet Holdings, Inc. $600,000,000 4.700% Notes due 2027 $550,000,000 5.050% Notes due 2030 $600,000,000 5.500% Notes due 2035 As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 PROSPECTUS SUPPLEMENT (To Prospectus dated February 25, 2022) $1,750,000,000 Zimmer Biomet Holdings, Inc. $600,000,000 4.700% Notes due 2027 $550,000,000 5.050% Notes due 2030 $600,000,000 5.500% Notes due 2035 We are offering for sale $600,000,000 aggregate principal amount of 4.700% notes due 2027 (the “2027 notes”), $550,
February 11, 2025	424B5	SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED FEBRUARY 11, 2025 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 The information in this preliminary prospectus supplement is not complete and may be changed. An effective registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer t
February 11, 2025	FWP	Zimmer Biomet Holdings, Inc. Pricing Term Sheet $600,000,000 4.700% Notes due 2027 $550,000,000 5.050% Notes due 2030 $600,000,000 5.500% Notes due 2035 February 11, 2025 Filed Pursuant to Rule 433 under the Securities Act of 1933, as amended Registration Statement No.
February 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm
February 6, 2025	EX-99.1	Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 [email protected] [email protected] Zach Weiner (908) 591-6955 [email protected] Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results • Fourth quarter net sales of $2.023 billion
January 29, 2025	EX-99.2	Disclaimer Cautionary Note Regarding Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including any statements Exhibit 99.2 ZIMMER BIOMET MOVING YOU MOVING YOU F FO OR RW WA AR RD D ZBH Acquisition of Paragon 28 2024 Investor Day January 28, 2025 Disclaimer Cautionary Note Regarding Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including any statements about us; Para
January 29, 2025	EX-99.1	Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28 Demonstrates Zimmer Biomet’s Commitment to Investing in Higher Growth End-Markets, with Expansion into ~$5 Billion Foot and Ankle Segment Expected to Enhance Zimmer Biomet’s Financial Exhibit 99.1 Zimmer Biomet: Media Investors Heather Zoumas-Lubeski 445-248-0577 [email protected] Kirsten Fallon 781-779-5562 [email protected] David DeMartino 646-531-6115 [email protected] Zach Weiner 908-591-6955 [email protected] Paragon 28: Media and Investors: Matt Brinckman 720-912-1332 [email protected] Zimmer Biomet Annou
January 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm
January 29, 2025	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm
January 29, 2025	DFAN14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm
January 29, 2025	EX-99.1	VOTING AGREEMENT Exhibit 99.1 Execution Version VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of January 28, 2025, is by and among Zimmer, Inc., a Delaware corporation (“Parent”), Gazelle Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and each of the undersigned stockholders (each, a “Stockholder”, and together the “Stockholders”) of the Com
January 29, 2025	EX-2.1	Agreement and Plan of Merger, dated as of January 28, 2025, by and among Zimmer, Inc., Gazelle Merger Sub I, Inc., Paragon 28, Inc. and Zimmer Biomet Holdings, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed January 29, 2025) Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER By and Among ZIMMER, INC., GAZELLE MERGER SUB I, INC., PARAGON 28, INC. and, solely for purposes of Section 8.15, ZIMMER BIOMET HOLDINGS, INC. Dated as of January 28, 2025 TABLE OF CONTENTS Page ARTICLE I THE MERGER 2 Section 1.01. The Merger 2 Section 1.02. Merger Closing 2 Section 1.03. Effective Time 3 Section 1.04. Effects of the Merge
January 29, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm
November 20, 2024	EX-4.2	Eleventh Supplemental Indenture, dated as of November 20, 2024, between Zimmer Biomet Holdings, Inc. and Computershare Trust Company, N.A., as trustee. EX-4.2 Exhibit 4.2 Execution Version ZIMMER BIOMET HOLDINGS, INC. €700,000,000 3.518% Notes due 2032 ELEVENTH SUPPLEMENTAL INDENTURE Dated as of November 20, 2024 to Indenture dated as of November 17, 2009 COMPUTERSHARE TRUST COMPANY, N.A. Trustee Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Application of this Eleventh Supplemental Indenture 1 SECTION
November 20, 2024	8-A12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ZIMMER BIOMET HOLDINGS, INC. (Exact Name of Reg UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ZIMMER BIOMET HOLDINGS, INC.
November 20, 2024	EX-4.3	Agency Agreement, dated as of November 20, 2024, by and among Zimmer Biomet Holdings, Inc., as issuer, U.S. Bank Europe DAC, UK Branch, as paying agent, U.S. Bank Trust Company, National Association, as registrar and transfer agent, and Computershare Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed November 20, 2024). EX-4.3 Exhibit 4.3 DATED NOVEMBER 20, 2024 ZIMMER BIOMET HOLDINGS, INC., AS ISSUER U.S. BANK EUROPE DAC, UK BRANCH, AS PAYING AGENT U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS TRANSFER AGENT U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS REGISTRAR - AND - COMPUTERSHARE TRUST COMPANY, N.A., AS TRUSTEE AGENCY AGREEMENT relating to Notes issued pursuant to a registration statement including
November 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 ZIMMER BIOMET H UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com
November 19, 2024	EX-1.1	Underwriting Agreement, dated as of November 13, 2024, among Zimmer Biomet Holdings, Inc., Barclays Bank PLC, Goldman Sachs & Co. LLC, HSBC Bank plc and RBC Europe Limited. Exhibit 1.1 Execution Version Zimmer Biomet Holdings, Inc. €700,000,000 3.518% Notes due 2032 Underwriting Agreement New York, New York November 13, 2024 Barclays Bank PLC Goldman Sachs & Co. LLC HSBC Bank plc RBC Europe Limited As representatives of the several underwriters named in Schedule I hereto c/o Barclays Bank PLC 1 Churchill Place London, E14 5HP United Kingdom Goldman Sachs & Co. LLC 20
November 19, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com
November 14, 2024	424B5	€700,000,000 Zimmer Biomet Holdings, Inc. 3.518% Notes due 2032 As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 PROSPECTUS SUPPLEMENT (To Prospectus dated February 25, 2022) €700,000,000 Zimmer Biomet Holdings, Inc. 3.518% Notes due 2032 We are offering for sale €700,000,000 aggregate principal amount of 3.518% notes due 2032 (the “notes”). We will pay interest on the notes annually in arrears on December 15 of each year, commencing
November 14, 2024	EX-FILING FEES	Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC.
November 13, 2024	SC 13G/A	ZBH / Zimmer Biomet Holdings, Inc. / DODGE & COX - SC 13G/A Passive Investment SC 13G/A 1 d812440dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* ZIMMER BIOMET HOLDINGS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 98956P102 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box
November 13, 2024	FWP	Zimmer Biomet Holdings, Inc. Pricing Term Sheet €700,000,000 3.518% Notes due 2032 November 13, 2024 Filed Pursuant to Rule 433 under the Securities Act of 1933, as amended Registration Statement No.
November 13, 2024	424B5	SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED NOVEMBER 13, 2024 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 The information in this preliminary prospectus supplement is not complete and may be changed. An effective registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer t
October 30, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm
October 30, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2024 Commission File Number 001-164 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2024 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporati
October 30, 2024	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of September 30, 2024 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet Internatio
October 30, 2024	EX-99.1	Zimmer Biomet Announces Third Quarter 2024 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski David DeMartino (445) 248-0577 (646) 531-6115 [email protected] [email protected] Zach Weiner (908) 591-6955 [email protected] Zimmer Biomet Announces Third Quarter 2024 Financial Results • Third quarter net sales of $1.824 billion increased 4.0%
August 15, 2024	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commi
August 15, 2024	EX-4.2	Tenth Supplemental Indenture, dated as of August 15, 2024, between Zimmer Biomet Holdings, Inc. and Computershare Trust Company, N.A., as trustee. Exhibit 4.2 ZIMMER BIOMET HOLDINGS, INC. $700,000,000 5.200% Notes due 2034 TENTH SUPPLEMENTAL INDENTURE Dated as of August 15, 2024 to Indenture dated as of November 17, 2009 COMPUTERSHARE TRUST COMPANY, N.A. Trustee Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Application of this Tenth Supplemental Indenture 1 SECTION 1.02. Definitions 2 SECTION 1.
August 14, 2024	EX-1.1	Underwriting Agreement, dated as of August 8, 2024, among Zimmer Biomet Holdings, Inc., Barclays Capital Inc., BNP Paribas Securities Corp., BofA Securities, Inc., Citigroup Global Markets Inc. and J.P. Morgan Securities LLC. Exhibit 1.1 [Execution] Zimmer Biomet Holdings, Inc. $700,000,000 5.200% Notes due 2034 Underwriting Agreement New York, New York August 8, 2024 Barclays Capital Inc. BNP Paribas Securities Corp. BofA Securities, Inc. Citigroup Global Markets Inc. J.P. Morgan Securities LLC As representatives of the several underwriters named in Schedule I hereto c/o Barclays Capital Inc. 745 Seventh Avenue New Yo
August 14, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commis
August 9, 2024	FWP	Zimmer Biomet Holdings, Inc. Pricing Term Sheet $700,000,000 5.200% Notes due 2034 August 8, 2024 Filed Pursuant to Rule 433 under the Securities Act of 1933, as amended Registration Statement No.
August 9, 2024	424B5	$700,000,000 Zimmer Biomet Holdings, Inc. 5.200% Notes due 2034 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 PROSPECTUS SUPPLEMENT (To Prospectus dated February 25, 2022) $700,000,000 Zimmer Biomet Holdings, Inc. 5.200% Notes due 2034 We are offering for sale $700,000,000 aggregate principal amount of 5.200% notes due 2034 (the “notes”). We will pay interest on the notes on March 15 and September 15 of each year,
August 9, 2024	EX-FILING FEES	Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC.
August 8, 2024	424B5	SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED AUGUST 8, 2024 424B5 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration Statement No.
August 7, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commis
August 7, 2024	EX-99.1	EXPLANATORY NOTE Exhibit 99.1 EXPLANATORY NOTE Zimmer Biomet Holdings, Inc. (“we”, “us”, “our”, the “Company” and other similar words) is filing this Exhibit 99.1 to its Current Report on Form 8-K (including this Exhibit 99.1, the “Form 8-K”) solely to recast certain financial information and related disclosures included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, origi
August 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commis
August 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2024 Commission File Number 001-16407 ZI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2024 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or
August 7, 2024	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of June 30, 2024 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International,
August 7, 2024	EX-99.1	Zimmer Biomet Announces Second Quarter 2024 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces Second Quarter 2024 Financial Results • Second quarter net sales of $1.942 billion increased 3.9% and 5.6% on a constant currency1 basis • Second quarter dilute
July 1, 2024	EX-10.2	364-Day Revolving Credit Agreement, dated as of June 28, 2024, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent Exhibit 10.2 EXECUTION VERSION 364-DAY REVOLVING CREDIT AGREEMENT dated as of June 28, 2024, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., MIZUHO BANK, LTD., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SECURITIE
July 1, 2024	EX-10.1	Five-Year Revolving Credit Agreement, dated as of June 28, 2024, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent Exhibit 10.1 EXECUTION VERSION FIVE-YEAR REVOLVING CREDIT AGREEMENT dated as of June 28, 2024, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., MIZUHO BANK, LTD., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SECURIT
July 1, 2024	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commiss
June 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commiss
June 20, 2024	EX-99.1	Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors (WARSAW, IN) June 20, 2024 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology
June 5, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Zimmer Biomet Holdings, Inc.
June 5, 2024	S-8	As filed with the Securities and Exchange Commission on June 5, 2024 As filed with the Securities and Exchange Commission on June 5, 2024 Registration No.
May 22, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 (State or other jurisdiction of incorporation) (Commission File Number) 345 East Main Street Warsaw, Indiana 46580 (Address of principal executive offices) (Zip Code) Chad F. Phipps Senio
May 22, 2024	EX-1.01	Conflict Minerals Report of Zimmer Biomet Holdings, Inc. Exhibit 1.01 ZIMMER BIOMET HOLDINGS, INC. Conflict Minerals Report For the Reporting Period from January 1, 2023 to December 31, 2023 This Conflict Minerals Report (this “Report”) of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet,” the “Company,” “we,” “our” or “us”) has been prepared pursuant to Rule 13p-1 and Form SD (collectively, the “Rule”) promulgated under the Securities Exchange Act of 1934,
May 15, 2024	EX-10.1	Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan, as amended and restated effective May 10, 2024 (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed May 15, 2024) Exhibit 10.1 ZIMMER BIOMET HOLDINGS, INC. EMPLOYEE STOCK PURCHASE PLAN (As amended and restated effective May 10, 2024) Section 1. Designation and Purpose. The name of this Plan is the Zimmer Biomet Holdings, Inc. Employee Stock Purchase Plan. The purpose of the Plan is to provide Employees of the Company and its Designated Subsidiaries with an opportunity to purchase Common Stock of the Company.
May 15, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commissi
May 2, 2024	EX-99.1	Zimmer Biomet Announces First Quarter 2024 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces First Quarter 2024 Financial Results • First quarter net sales of $1.889 billion increased 3.2% and 4.4% on a constant currency1 basis • First quarter diluted e
May 2, 2024	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of March 31, 2024 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International,
May 2, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commissio
May 2, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2024 Commission File Number 001-16407 Z UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2024 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation o
March 27, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 27, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin
February 23, 2024	EX-10.52	Amendment to Change in Control Severance Agreement dated February 19, 2024 between Zimmer GmbH and Wilfred van Zuilen Exhibit 10.52 Amendment to Change in Control Severance Agreement Recitals (A) On 5 May 2021, Zimmer GmbH ("Employer" or "Company" as case may be) and Wilfred van Zuilen ("Executive"; the Employer and the Executive each individually, a "Party" and together, the "Parties") have entered into a Change in Control Severance Agreement ("CIC Agreement"). (B) The Parties know wish to amend the CIC Agreemen
February 23, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2023 Commission file number 001-16407 ZIMMER BIOMET HOL I have UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2023 Commission file number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State of Incorporation) (IRS Employer Identification No
February 23, 2024	EX-97.1	Zimmer Biomet Holdings, Inc. Compensation Recovery Policy, effective October 2, 2023 Exhibit 97.1 ZIMMER BIOMET HOLDINGS, INC. COMPENSATION RECOVERY POLICY Policy The Compensation and Management Development Committee (the “Committee”) of the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”) has adopted this Compensation Recovery Policy (this “Policy”) pursuant to Rule 10D-1 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”),
February 23, 2024	EX-10.51	Form of Amendment to Change in Control Severance Agreement with Ivan Tornos, Suketu Upadhyay, Rachel Ellingson, Lori Winkler and Paul Stellato Exhibit 10.51 AMENDMENT TO CHANGE IN CONTROL SEVERANCE AGREEMENT This Amendment to Change in Control Severance Agreement (this “Amendment”) is made by and between ZIMMER BIOMET HOLDINGS, INC., a Delaware corporation (the “Company”) and (the “Executive”), as of (the “Effective Date”). The Company and Executive are hereinafter collectively referred to as the “Parties.” Recitals A. The Company and th
February 23, 2024	EX-10.53	Deed of Amendment dated February 19, 2024 between Zimmer Asia (HK) Limited and Sang-Uk Yi Exhibit 10.53 Deed of Amendment This Deed is made on February 19, 2024 Between: (1) Zimmer Asia (HK) Limited, a company incorporated in Hong Kong (registered number 52194097) (the "Company"); and (2) Yi Sang-Uk (the “Executive”). Background: (A) The Company and the Executive have entered into a Change in Control Severance Agreement on June 15, 2020 (the "Agreement"). (B) The Company and the Execut
February 23, 2024	EX-10.54	Form of Change in Control Severance Agreement with Kevin Thornal (incorporated by reference to Exhibit 10.54 to the Registrant’s Annual Report on Form 10-K filed February 23, 2024) Exhibit 10.54 CHANGE IN CONTROL SEVERANCE AGREEMENT THIS AGREEMENT, dated as of , is made by and between ZIMMER BIOMET HOLDINGS, INC., a Delaware corporation (the “Company”), and (the “Executive”). The capitalized words and terms used throughout this Agreement are defined in Article XIII. Recitals A. The Company considers it essential to the best interests of its stockholders to foster the continu
February 23, 2024	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of December 31, 2023 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Avitus Orthopaedics, Inc. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet Internation
February 13, 2024	SC 13G/A	ZBH / Zimmer Biomet Holdings, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02333-zimmerbiometholdings.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Zimmer Biomet Holdings Inc Title of Class of Securities: Common Stock CUSIP Number: 98956P102 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box
February 13, 2024	SC 13G	ZBH / Zimmer Biomet Holdings, Inc. / DODGE & COX - SC 13G Passive Investment SC 13G 1 d719732dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 0 )* ZIMMER BIOMET HOLDINGS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 98956P102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
February 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm
February 8, 2024	EX-99.1	Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results • Fourth quarter net sales of $1.940 billion increased 6.3% and 6.1% on a constant currency1 basis • Fourth
January 5, 2024	EX-99.1	Zimmer Biomet Announces Appointment of Louis A. Shapiro to Board of Directors EX-99.1 Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces Appointment of Louis A. Shapiro to Board of Directors (WARSAW, IN) January 5, 2024 — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical
January 5, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Employe
December 1, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Com
December 1, 2023	EX-4.2	Ninth Supplemental Indenture, dated as of December 1, 2023, between Zimmer Biomet Holdings, Inc. and Computershare Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed December 1, 2023) EXHIBIT 4.2 [Execution] ZIMMER BIOMET HOLDINGS, INC. $500,000,000 5.350% Notes due 2028 NINTH SUPPLEMENTAL INDENTURE Dated as of December 1, 2023 to Indenture dated as of November 17, 2009 COMPUTERSHARE TRUST COMPANY, N.A. Trustee Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Application of this Ninth Supplemental Indenture 1 SECTION 1.02. Definitions 2
December 1, 2023	EX-1.1	Underwriting Agreement, dated as of November 28, 2023, among Zimmer Biomet Holdings, Inc., Barclays Capital Inc., Goldman Sachs & Co. LLC, Mizuho Securities USA LLC and Morgan Stanley & Co. LLC. EXHIBIT 1.1 [Execution] Zimmer Biomet Holdings, Inc. $500,000,000 5.350% Notes due 2028 Underwriting Agreement New York, New York November 28, 2023 Barclays Capital Inc. Goldman Sachs & Co. LLC Mizuho Securities USA LLC Morgan Stanley & Co. LLC As representatives of the several underwriters named in Schedule I hereto c/o Barclays Capital Inc. 745 Seventh Avenue New York, New York 10019 Goldman Sac
November 30, 2023	EX-FILING FEES	Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amo Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC.
November 30, 2023	424B5	$500,000,000 Zimmer Biomet Holdings, Inc. 5.350% Notes due 2028 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 PROSPECTUS SUPPLEMENT (To Prospectus dated February 25, 2022) $500,000,000 Zimmer Biomet Holdings, Inc. 5.350% Notes due 2028 We are offering for sale $500,000,000 aggregate principal amount of 5.350% notes due 2028 (the “notes”). We will pay interest on the notes on June 1 and December 1 of each year, comm
November 28, 2023	424B5	SUBJECT TO COMPLETION PRELIMINARY PROSPECTUS SUPPLEMENT, DATED NOVEMBER 28, 2023 Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 The information in this preliminary prospectus supplement is not complete and may be changed. An effective registration statement relating to these securities has been filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer t
November 28, 2023	FWP	Zimmer Biomet Holdings, Inc. Pricing Term Sheet $500,000,000 5.350% Notes due 2028 November 28, 2023 Filed Pursuant to Rule 433 under the Securities Act of 1933, as amended Registration Statement No.
November 7, 2023	EX-10.6	Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors, as amended August 25, 2023 (incorporated by reference to Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q filed November 7, 2023) Exhibit 10.6 ZIMMER BIOMET HOLDINGS, INC. DEFERRED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS (As Amended on August 25, 2023) Section 1. Eligibility. Any member of the Board of Directors (the “Board”) of Zimmer Biomet Holdings, Inc. (the “Company”) who is not an officer or employee of the Company or a subsidiary thereof is eligible to participate in the Plan and will be a participant. Section 2.
November 7, 2023	EX-99.1	Zimmer Biomet Announces Third Quarter 2023 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Zach Weiner (703) 346-3127 (908) 591-6955 [email protected] [email protected] Heather Zoumas-Lubeski (445) 248-0577 [email protected] Zimmer Biomet Announces Third Quarter 2023 Financial Results • Third quarter net sales of $1.754 billion increased 5
November 7, 2023	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of September 30, 2023 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Armada Merger Corp. Delaware Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International, I
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm
November 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 Commission File Number 001-164 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporati
August 22, 2023	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Employe
August 22, 2023	EX-10.1	Offer Letter, dated as of August 21, 2023, by and between Zimmer Biomet Holdings, Inc. and Ivan Tornos (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed August 22, 2023) Exhibit 10.1 Confidential August 21, 2023 Ivan Tornos Dear Ivan, We are pleased to offer you the role of President and Chief Executive Officer (CEO) of Zimmer Biomet Holdings, Inc. (the Company or Zimmer Biomet). You will report directly to the Company’s Board of Directors. Your salary grade will be level Z01. Your start date as President and CEO will be Tuesday, August 22, 2023 (the “Effective Da
August 22, 2023	EX-99.1	Zimmer Biomet Announces Leadership Transition Chief Operating Officer Ivan Tornos Appointed President and CEO; Elected to the Board of Directors Chief Financial Officer Suketu (Suky) Upadhyay’s Role Expands to CFO and EVP, Finance, Operations & Suppl Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Heather Zoumas-Lubeski (445) 248-0577 [email protected] Zach Weiner (908) 591-6955 [email protected] Zimmer Biomet Announces Leadership Transition Chief Operatin
August 22, 2023	EX-10.2	Change in Control Severance Agreement, dated as of August 21, 2023, by and between Zimmer Biomet Holdings, Inc. and Ivan Tornos (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed August 22, 2023) Exhibit 10.2 CHANGE IN CONTROL SEVERANCE AGREEMENT THIS AGREEMENT, dated as of August 21, 2023, is made by and between ZIMMER BIOMET HOLDINGS, INC., a Delaware corporation (the “Company”), and Ivan Tornos (the “Executive”). The capitalized words and terms used throughout this Agreement are defined in Article XIII. Recitals A. The Company considers it essential to the best interests of its stockhol
August 22, 2023	EX-10.3	Chief Executive Officer Confidentiality, Non-Competition and Non-Solicitation Agreement, dated as of August 21, 2023, by and between Zimmer Biomet Holdings, Inc. and Ivan Tornos (incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K filed August 22, 2023) Exhibit 10.3 CHIEF EXECUTIVE OFFICER CONFIDENTIALITY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT This Chief Executive Officer Confidentiality, Non-Competition and Non-Solicitation Agreement (“Agreement”) is made by and between Zimmer Biomet Holdings, Inc., a corporation having its principal headquarters in Warsaw, Indiana, and Ivan Tornos (“Executive”). Recitals A. For purposes of this Agreeme
August 1, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 Commission File Number 001-16407 ZI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2023 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or
August 1, 2023	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of June 30, 2023 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International, Inc. Delaware Biomet Leasing, Inc.
August 1, 2023	EX-99.1	Zimmer Biomet Announces Second Quarter 2023 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Zach Weiner (703) 346-3127 (908) 591-6955 [email protected] [email protected] Heather Zoumas-Lubeski (445) 248-0577 [email protected] Zimmer Biomet Announces Second Quarter 2023 Financial Results • Second quarter net sales of $1.870 billion increased
August 1, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commis
July 10, 2023	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commissi
July 10, 2023	EX-10.2	364-Day Revolving Credit Agreement, dated as of July 7, 2023, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent EX-10.2 Exhibit 10.2 EXECUTION VERSION 364-DAY REVOLVING CREDIT AGREEMENT dated as of July 7, 2023, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., MIZUHO BANK, LTD., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SE
July 10, 2023	EX-10.1	Five-Year Revolving Credit Agreement, dated as of July 7, 2023, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent EX-10.1 Exhibit 10.1 EXECUTION VERSION FIVE-YEAR REVOLVING CREDIT AGREEMENT dated as of July 7, 2023, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., CITIBANK, N.A., MIZUHO BANK, LTD., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC
June 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 ZIMMER BIOMET HOLDI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commiss
June 16, 2023	424B5	107,822 Shares Zimmer Biomet Holdings, Inc. Common Stock 424B5 Table of Contents As filed pursuant to Rule 424(b)(5) Registration Statement No.
June 16, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Zimmer Biomet Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Propos EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Zimmer Biomet Holdings, Inc.
May 19, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 (State or other jurisdiction of incor SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 (State or other jurisdiction of incorporation) (Commission File Number) 345 East Main Street Warsaw, Indiana 46580 (Address of principal executive offices) (Zip Code) Chad F. Phipps Se
May 19, 2023	SC 13G/A	ZIMV / ZimVie Inc / ZIMMER BIOMET HOLDINGS, INC. - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ZimVie Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98888T107 (CUSIP Number) February 1, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil
May 19, 2023	EX-1.01	Conflict Minerals Report of Zimmer Biomet Holdings, Inc. Exhibit 1.01 ZIMMER BIOMET HOLDINGS, INC. Conflict Minerals Report For the Reporting Period from January 1, 2022 to December 31, 2022 This Conflict Minerals Report (this “Report”) of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet,” the “Company,” “we,” “our” or “us”) has been prepared pursuant to Rule 13p-1 and Form SD (collectively, the “Rule”) promulgated under the Securities Exchange Act of 1934,
May 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 ZIMMER BIOMET HOLDIN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Employer o
May 2, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commissio
May 2, 2023	EX-99	Zimmer Biomet Announces First Quarter 2023 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 [email protected] [email protected] Zimmer Biomet Announces First Quarter 2023 Financial Results
May 2, 2023	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of March 31, 2023 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International Orthopedics, LLC Delaware Biomet In
May 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2023 Commission File Number 001-16407 Z UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2023 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation o
March 30, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant t o Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant t o Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 1
March 30, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registr DEFA14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 30, 2023	DEF 14A	PDF OF DEFINITIVE PROXY STATEMENT Notice of 2023 Annual Meeting of Shareholders and Proxy Statement Friday, May 12, 2023 8 a.
February 24, 2023	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of December 31, 2022 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Bayeux Acquisition Corp. Virginia Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet Internationa
February 24, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2022 Commission file number 001-16407 ZIMMER BIOMET HOL I have UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2022 Commission file number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State of Incorporation) (IRS Employer Identification No
February 24, 2023	EX-3	Restated Bylaws of Zimmer Biomet Holdings, Inc., effective December 14, 2022 (incorporated by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K filed February 24, 2023) Exhibit 3.2 RESTATED BYLAWS OF ZIMMER BIOMET HOLDINGS, INC. (hereinafter called the “Corporation”) Effective: December 14, 2022 ARTICLE I Offices and Records SECTION 1.01. Registered Office. The registered office of the Corporation in the State of Delaware is located at 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808, and the registered agent at such address is Cor
February 24, 2023	EX-4	Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 Exhibit 4.1 Description of the Registrant’s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 As of December 31, 2022, Zimmer Biomet Holdings, Inc. (the “Company,” “we,” “our” and “us” refer solely to Zimmer Biomet Holdings, Inc.) maintained three classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (
February 15, 2023	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Zimmer Biomet Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Propos EX-FILING FEES 2 d460473dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Zimmer Biomet Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price
February 15, 2023	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Com
February 15, 2023	424B5	1,059,992 Shares Zimmer Biomet Holdings, Inc. Common Stock 424B5 1 d460473d424b5.htm 424B5 Table of Contents As filed pursuant to Rule 424(b)(5) Registration Statement No. 333-263051 PROSPECTUS SUPPLEMENT (To Prospectus dated February 25, 2022) 1,059,992 Shares Zimmer Biomet Holdings, Inc. Common Stock This prospectus supplement relates to the offering and resale by the selling stockholders identified herein of up to 1,059,992 shares (the “offered shares”
February 9, 2023	SC 13G/A	ZBH / Zimmer Biomet Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02299-zimmerbiometholdings.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Zimmer Biomet Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 98956P102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate bo
February 3, 2023	EX-99.1	Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Heather Zoumas-Lubeski (445) 248-0577 [email protected] Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results • Fourth quarter net sales from continui
February 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2023 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm
January 27, 2023	SC 13G	ZIMV / ZimVie Inc / ZIMMER BIOMET HOLDINGS, INC. - SC 13G Passive Investment SC 13G 1 d447736dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ZimVie Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98888T107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
December 14, 2022	EX-3.1	Restated Bylaws of Zimmer Biomet Holdings, Inc., effective December 14, 2022 Exhibit 3.1 RESTATED BYLAWS OF ZIMMER BIOMET HOLDINGS, INC. (hereinafter called the ?Corporation?) Effective: May 17, 2021 December 14, 2022 ARTICLE I Offices and Records SECTION 1.01. Registered Office. The registered office of the Corporation in the State of Delaware is located at 251 Little Falls Drive, City of Wilmington, County of New Castle, Delaware 19808, and the registered agent at such a
December 14, 2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Emplo
December 13, 2022	EX-99.25	EX-99.25 NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 27, 2022, pursuant to the provisions of Rule 12d2-2 (a).
November 7, 2022	SC 13G/A	ZBH / Zimmer Biomet Holdings Inc / JPMORGAN CHASE & CO - FILING ZIMMER BIOMET HOLDINGS, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* ZIMMER BIOMET HOLDINGS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 98956P102 (CUSIP Number) October 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
November 2, 2022	EX-99.1	Zimmer Biomet Announces Third Quarter 2022 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Heather Zoumas-Lubeski (445) 248-0577 [email protected] Zimmer Biomet Announces Third Quarter 2022 Financial Results • Third quarter net sales from continuing operations of
November 2, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2022 Commission File Number 001-164 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2022 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporati
November 2, 2022	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of September 30, 2022 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International Orthopedics, LLC Delaware Biome
November 2, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Comm
August 22, 2022	EX-10.2	364-Day Revolving Credit Agreement, dated as of August 19, 2022, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent EXHIBIT 10.2 364-DAY REVOLVING CREDIT AGREEMENT dated as of August 19, 2022, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., CITIBANK, N.A., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SECURITIES (USA) INC., MIZUHO BANK, LTD., MO
August 22, 2022	EX-10.1	Five-Year Revolving Credit Agreement, dated as of August 19, 2022, among Zimmer Biomet Holdings, Inc., the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent EXHIBIT 10.1 FIVE-YEAR REVOLVING CREDIT AGREEMENT dated as of August 19, 2022, among ZIMMER BIOMET HOLDINGS, INC., THE LENDERS PARTY HERETO and JPMORGAN CHASE BANK, N.A., as Administrative Agent JPMORGAN CHASE BANK, N.A., BOFA SECURITIES, INC., BARCLAYS BANK PLC, BNP PARIBAS SECURITIES CORP., CITIBANK, N.A., DNB MARKETS, INC., GOLDMAN SACHS BANK USA, HSBC SECURITIES (USA) INC., MIZUHO BANK, LTD.,
August 22, 2022	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commi
August 2, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 Commission File Number 001-16407 ZI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation or
August 2, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 02, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-16407 13-4151777 (State or Other Jurisdiction of Incorporation) (Commi
August 2, 2022	EX-99.1	Zimmer Biomet Announces Second Quarter 2022 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces Second Quarter 2022 Financial Results ? Second quarter net sales from continuing operations of $1.782 billion incre
August 2, 2022	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of June 30, 2022 Name of Subsidiary Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International Orthopedics, LLC Delaware Biomet Inte
June 22, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commiss
June 22, 2022	EX-99.1	EXPLANATORY NOTE Exhibit 99.1 EXPLANATORY NOTE Zimmer Biomet Holdings, Inc. (?we?, ?us?, ?our?, the ?Company? and other similar words) is filing this Exhibit 99.1 to its Current Report on Form 8-K (including this Exhibit 99.1, the ?Form 8-K?) solely to recast certain financial information and related disclosures included in the Company?s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, origi
May 23, 2022	EX-1.01	Conflict Minerals Report of Zimmer Biomet Holdings, Inc. EX-1.01 2 d291956dex101.htm EX-1.01 Exhibit 1.01 ZIMMER BIOMET HOLDINGS, INC. Conflict Minerals Report For the Reporting Period from January 1, 2021 to December 31, 2021 This Conflict Minerals Report (this “Report”) of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet,” the “Company,” “we,” “our” or “us”) has been prepared pursuant to Rule 13p-1 and Form SD (collectively, the “Rule”) promulgated under
May 23, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 (State or other jurisdiction of incor UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 (State or other jurisdiction of incorporation) (Commission File Number) 345 East Main Street Warsaw, Indiana 46580 (Address of principal executive offices) (Zip Code) Chad F. Phipps Senio
May 19, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commissi
May 16, 2022	EX-99.1	Zimmer Biomet Announces Appointment of New Chief Accounting Officer Paul Stellato Joins Zimmer Biomet as Vice President, Controller and Chief Accounting Officer Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox 703-346-3127 215-275-2431 [email protected] [email protected] Ezgi Yagci 617-549-2443 [email protected] Zimmer Biomet Announces Appointment of New Chief Accounting Officer Paul Stellato Joins Zimmer Biomet as Vice President, Controller and Chief Acc
May 16, 2022	EX-10.1	Offer Letter by and between Zimmer Biomet Holdings, Inc. and Paul Stellato dated as of April 5, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed May 16, 2022) Exhibit 10.1 April 5, 2022 Paul Stellato Dear Paul, We are pleased to offer you the position of Vice President, Controller and Chief Accounting Officer for Zimmer Biomet Holdings, Inc., reporting to me. In this position, you will be paid a gross annual salary of $375,000 in bi-weekly installments and your salary grade will be Z05. Your position is exempt, as such, your annual salary is intended to
May 16, 2022	EX-10.4	Form of Confidentiality, Non-Competition and Non-Solicitation Agreement with Paul Stellato (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed May 16, 2022) Exhibit 10.4 CORPORATE EXECUTIVE CONFIDENTIALITY, NON-COMPETITION AND NON-SOLICITATION AGREEMENT This Corporate Executive Confidentiality, Non-Competition and Non-Solicitation Agreement (?Agreement?) is made by and between Zimmer, Inc., a corporation having its principal headquarters in Warsaw, Indiana, and (?Employee?). Recitals A. For purposes of this Agreement, the term ?Company? means Zimmer,
May 16, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commissi
May 5, 2022	EX-10.4	Fourth Amendment and Limited Waiver, dated as of January 19, 2022, between Zimmer Biomet G.K. and Sumitomo Mitsui Banking Corporation, to the JP¥11,700,000,000 Amended and Restated Term Loan Agreement dated as of September 22, 2017, as amended by the First Amendment dated as of January 10, 2018, the Second Amendment and Limited Waiver dated as of February 25, 2020 and the Third Amendment dated as of April 28, 2020 EXHIBIT 10.4 FOURTH AMENDMENT AND LIMITED WAIVER (the "Fourth Amendment"), dated as of January 19, 2022, between ZIMMER BIOMET G.K. (the "Borrower") and SUMITOMO MITSUI BANKING CORPORATION (the "Bank"), to the JP?11,700,000,000 AMENDED AND RESTATED TERM LOAN AGREEMENT dated as of September 22, 2017, as amended by the First Amendment dated as of January 10, 2018, the Second Amendment and Limited Wa
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 Commission File Number 001-16407 Z UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2022 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of incorporation o
May 5, 2022	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of March 31, 2022 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biomet International Orthopedics, LLC Delaware Biomet In
May 5, 2022	EX-10.3	Third Amendment and Limited Waiver, dated as of January 19, 2022, between Zimmer Biomet G.K. and Sumitomo Mitsui Banking Corporation, to the JP¥21,300,000,000 Term Loan Agreement dated as of September 22, 2017, as amended by the First Amendment and Limited Waiver dated as of February 25, 2020 and the Second Amendment dated as of April 28, 2020 EXHIBIT 10.3 THIRD AMENDMENT AND LIMITED WAIVER (the "Third Amendment"), dated as of January 19, 2022, between ZIMMER BIOMET G.K. (the "Borrower") and SUMITOMO MITSUI BANKING CORPORATION (the "Bank"), to the JP?21,300,000,000 TERM LOAN AGREEMENT dated as of September 22, 2017, as amended by the First Amendment and Limited Waiver dated as of February 25, 2020 and the Second Amendment dated as of Ap
May 5, 2022	EX-10.2	Amended and Restated Zimmer Biomet Deferred Compensation Plan, effective as of January 1, 2022 (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q filed May 5, 2022) EXHIBIT 10.2 ZIMMER BIOMET DEFERRED COMPENSATION PLAN Effective as of January 1, 2022 TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND CONSTRUCTION 1 1.1 Definitions.. 1 1.2 Rules of Construction. 5 ARTICLE II. PARTICIPATION 5 2.1 In General. 5 2.2 Participation. A 5 2.3. Transferred Employees. 6 2.4. Amendment of Eligibility Criteria.. 6 ARTICLE III. DEFERRAL ELECTIONS AND COMPANY MATCHING CONTR
May 5, 2022	EX-10.1	Amendment to Restated Zimmer Biomet Holdings, Inc. Executive Severance Plan (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q filed May 5, 2022) EXHIBIT 10.1 Amendment to the Zimmer Biomet Holdings, Inc. Executive Severance Plan Whereas, Zimmer Biomet Holdings, Inc. (the ?Company?) established and maintains the Zimmer Biomet Holdings, Inc. Executive Severance Plan (the ?Plan?), as effective May 14, 2018; and Whereas, the Plan delegates the Compensation and Management Development Committee (the ?Compensation Committee?) with the authority t
May 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Employer of
May 3, 2022	EX-99.1	Zimmer Biomet Announces First Quarter 2022 Financial Results 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces First Quarter 2022 Financial Results ? First quarter net sales from continuing operations of $1.663 billion increas
April 28, 2022	EX-99.1	ZIMMER BIOMET HOLDINGS, INC. Exhibit 99.1 As previously announced, on March 1, 2022, Zimmer Biomet Holdings, Inc. (the ?Company?) completed the separation (the ?Separation?) of its spine and dental businesses through the distribution by the Company of 80.3% of the outstanding shares of common stock of ZimVie Inc. (?ZimVie?) to the Company?s stockholders at the close of business on February 15, 2022 (the ?Record Date?). The di
April 28, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Employer
April 8, 2022	SC 13G/A	ZBH / Zimmer Biomet Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Zimmer Biomet Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 98956P102 Date of Event Which Requires Filing of this Statement: March 31, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fil
March 29, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registr DEFA14A 1 d260779ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as
March 29, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registr DEF 14A 1 d260779ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Com
March 29, 2022	DEF 14A	PDF OF DEFINITIVE PROXY STATEMENT
March 1, 2022	EX-10.10	Waiver, dated as of February 25, 2022, by and between Zimmer Biomet Holdings, Inc., the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent. EX-10.10 12 d650132dex1010.htm EX-10.10 Exhibit 10.10 WAIVER dated as of February 25, 2022 (this “Waiver”), to the 364-DAY REVOLVING CREDIT AGREEMENT dated as of August 20, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), among ZIMMER BIOMET HOLDINGS, INC., a Delaware corporation (the “Borrower”), the LENDERS party hereto and JPMORGAN CHASE
March 1, 2022	EX-10.7	Reverse Transition Manufacturing and Supply Agreement, dated as of March 1, 2022, by and between Zimmer, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.7 to the Registrant’s Current Report on Form 8-K filed March 1, 2022) Exhibit 10.7 REVERSE TRANSITION MANUFACTURING AND SUPPLY AGREEMENT dated as of March 1, 2022 by and between ZIMVIE INC. and ZIMMER, INC. Table of Contents Page ARTICLE I DEFINITIONS; RULES OF CONSTRUCTION 1 1.1 Definitions 1 1.2 Other Terms 4 1.3 Rules of Construction 4 ARTICLE II MANUFACTURING 4 2.1 General 4 2.2 Purchase Obligation 4 2.3 Volume Limitation; Capacity; Projects 5 2.4 Product Improv
March 1, 2022	EX-10.1	Tax Matters Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed March 1, 2022) Exhibit 10.1 TAX MATTERS AGREEMENT DATED AS OF MARCH 1, 2022 BY AND BETWEEN ZIMMER BIOMET HOLDINGS, INC. AND ZIMVIE INC. Table of Contents Page TAX MATTERS AGREEMENT 1 RECITALS Section 1. Definition of Terms 2 Section 2. Allocation of Tax Liabilities 10 Section 2.01 General Rule 10 Section 2.02 Allocation of United States Federal Income Taxes and Federal Other Tax 10 Section 2.03 Allocation of Sta
March 1, 2022	EX-10.6	Transition Manufacturing and Supply Agreement, dated as of March 1, 2022, by and between Zimmer, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.6 to the Registrant’s Current Report on Form 8-K filed March 1, 2022) Exhibit 10.6 TRANSITION MANUFACTURING AND SUPPLY AGREEMENT dated as of March 1, 2022 by and between ZIMMER, INC. and ZIMVIE INC. Table of Contents Page ARTICLE I DEFINITIONS; RULES OF CONSTRUCTION 1 1.1 Definitions 1 1.2 Other Terms 5 1.3 Rules of Construction 5 ARTICLE II MANUFACTURING 5 2.1 General 5 2.2 Purchase Obligation 5 2.3 Volume Limitation; Capacity; Projects 5 2.4 Product Improvements,
March 1, 2022	EX-10.2	Employee Matters Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed March 1, 2022) Exhibit 10.2 EMPLOYEE MATTERS AGREEMENT BY AND BETWEEN ZIMMER BIOMET HOLDINGS, INC. AND ZIMMER BIOMET SPINE, INC. DATED AS OF MARCH 1, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.01 Defined Terms 1 Section 1.02 References, Interpretation 5 Section 1.03 Relation to Other Documents 5 ARTICLE II GENERAL PRINCIPLES 6 Section 2.01 Allocation of Assets and Liabilities 6 Section 2.02 Em
March 1, 2022	EX-10.8	Transitional Trademark License Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.8 to the Registrant’s Current Report on Form 8-K filed March 1, 2022) EX-10.8 10 d650132dex108.htm EX-10.8 Exhibit 10.8 Dated March / 1 / 2022 TRANSITIONAL TRADEMARK LICENSE AGREEMENT by and between ZIMMER BIOMET HOLDINGS, INC. and ZIMVIE INC. TABLE OF CONTENTS 1. Definitions 1 2. License Grant 3 3. Restrictions 5 4. Ownership 6 5. Quality Control 6 6. Representations and Warranties; Covenants 7 7. Limitation of Liability 8 8. Confidentiality 8 9. Term and Terminati
March 1, 2022	EX-10.9	Waiver, dated as of February 25, 2022, by and between Zimmer Biomet Holdings, Inc., the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent. Exhibit 10.9 WAIVER dated as of February 25, 2022 (this ?Waiver?), to the FIVE-YEAR REVOLVING CREDIT AGREEMENT dated as of August 20, 2021 (as amended, restated, supplemented or otherwise modified from time to time, the ?Credit Agreement?), among ZIMMER BIOMET HOLDINGS, INC., a Delaware corporation (the ?Borrower?), the LENDERS party hereto and JPMORGAN CHASE BANK, N.A., as the Administrative Agen
March 1, 2022	EX-99.1	345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zi Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces Completion of ZimVie Spinoff WARSAW, IN (March 1, 2022) ? Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a globa
March 1, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Commiss
March 1, 2022	EX-10.3	Transition Services Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K filed March 1, 2022) Exhibit 10.3 TRANSITION SERVICES AGREEMENT This Transition Services Agreement (this ?Agreement?) is entered into as of March 1, 2022 (the ?Effective Date?), by and between Zimmer Biomet Holdings, Inc., a corporation organized under the laws of the State of Delaware (?Parent?), and ZimVie Inc., a corporation organized under the laws of the State of Delaware (?SpinCo?). Parent and SpinCo are each re
March 1, 2022	EX-10.5	Stockholder and Registration Rights Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.5 to the Registrant’s Current Report on Form 8-K filed March 1, 2022) Exhibit 10.5 STOCKHOLDER AND REGISTRATION RIGHTS AGREEMENT BY AND BETWEEN ZIMMER BIOMET HOLDINGS, INC. AND ZIMVIE INC. DATED AS OF MARCH 1, 2022 TABLE OF CONTENTS Page Article I DEFINITIONS 1 Article II REGISTRATION RIGHTS 5 Section 2.01 Registration 5 Section 2.02 Piggyback Registrations 8 Section 2.03 Registration Procedures 9 Section 2.04 Underwritten Offerings or Exchange Offers 13 Section 2.0
March 1, 2022	EX-2.1	Separation and Distribution Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K filed March 1, 2022) Exhibit 2.1 SEPARATION AND DISTRIBUTION AGREEMENT BY AND BETWEEN ZIMMER BIOMET HOLDINGS, INC. AND ZIMVIE INC. DATED AS OF MARCH 1, 2022 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 ARTICLE II THE SEPARATION 15 2.1 Transfer of Assets and Assumption of Liabilities 15 2.2 SpinCo Assets; Parent Assets 17 2.3 SpinCo Liabilities; Parent Liabilities 19 2.4 Deferred Markets. 21 2.5 Approvals and Notific
March 1, 2022	EX-10.4	Intellectual Property Matters Agreement, dated as of March 1, 2022, by and between Zimmer Biomet Holdings, Inc. and ZimVie Inc. (incorporated by reference to Exhibit 10.4 to the Registrant’s Current Report on Form 8-K filed March 1, 2022) Exhibit 10.4 Dated March / 1 / 2022 Intellectual Property Matters Agreement between ZIMMER BIOMET HOLDINGS, INC. and ZIMVIE INC. TABLE OF CONTENTS 1. Definitions 1 2. License Grants 4 3. Intellectual Property 5 4. Representations and Warranties; Covenants 7 5. LIMITATION OF LIABILITY 7 6. Confidentiality 7 7. Residual Knowledge 8 8. Term and Termination; Remedies 9 9. Miscellaneous 9 INTELLECTUAL
February 25, 2022	EX-25.1	Statement of Eligibility of Computershare Trust Company, N.A. on Form T-1 for Debt Securities. Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) N
February 25, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2021 Commission file number 001-16407 ZIMMER BIOMET HOL I have UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For year ended December 31, 2021 Commission file number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State of Incorporation) (IRS Employer Identification No
February 25, 2022	EX-FILING FEES	Calculation of Filing Fee Table. EX-FILING FEES 5 d194472dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ZIMMER BIOMET HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximu
February 25, 2022	EX-10.40	Form of Restricted Stock Unit Award Agreement (three-year vesting) under the Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan (incorporated by reference to Exhibit 10.40 to the Registrant’s Annual Report on Form 10-K filed February 25, 2022) Exhibit 10.40 ZIMMER BIOMET HOLDINGS, INC. 2009 STOCK INCENTIVE PLAN THREE-YEAR RESTRICTED STOCK UNIT AWARD Zimmer Biomet Holdings, Inc. (the ?Company?) granted you this restricted stock unit (?RSU?) award (?Award?) pursuant to the Company?s 2009 Stock Incentive Plan (?Plan?). Each RSU represents an unfunded, unsecured promise by the Company to deliver one share of Common Stock (?Share?) to you, s
February 25, 2022	EX-10.38	Form of Performance-Based Restricted Stock Unit Award Agreement (2022) under the Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan (incorporated by reference to Exhibit 10.38 to the Registrant’s Annual Report on Form 10-K filed February 25, 2022) Exhibit 10.38 ZIMMER BIOMET HOLDINGS, INC. 2009 STOCK INCENTIVE PLAN THREE-YEAR PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD Zimmer Biomet Holdings, Inc. (the ?Company?) grants you this restricted stock unit (?RSU?) award (?Award?) pursuant to the Company?s 2009 Stock Incentive Plan (?Plan?). Each RSU represents an unfunded, unsecured promise by the Company to deliver one share of Common Stock (?
February 25, 2022	EX-10.34	Form of Nonqualified Stock Option Award Agreement (three-year vesting) under the Zimmer Biomet Holdings, Inc. 2009 Stock Incentive Plan (incorporated by reference to Exhibit 10.34 to the Registrant’s Annual Report on Form 10-K filed February 25, 2022) Exhibit 10.34 ZIMMER BIOMET HOLDINGS, INC. 2009 STOCK INCENTIVE PLAN THREE-YEAR NONQUALIFIED STOCK OPTION GRANT Zimmer Biomet Holdings, Inc. (the ?Company?) grants you this option (this ?Option?) to purchase fully paid and non-assessable shares of the Company?s common stock, par value $0.01 per share (the ?Common Stock?) pursuant to the Company?s 2009 Stock Incentive Plan (the ?Plan?), subject to
February 25, 2022	EX-21	List of Subsidiaries of Zimmer Biomet Holdings, Inc. Exhibit 21 Subsidiaries of Zimmer Biomet Holdings, Inc. As of December 31, 2021 Name of Subsidiary1 Jurisdiction of Formation Domestic subsidiaries: A&E Advanced Closure Systems, LLC Delaware A&E Medical Corp. New Jersey Alto Development Corp. New Jersey Biomet 3i, LLC Florida dba Zimmer Biomet Dental Biomet Biologics, LLC Indiana Biomet CV Holdings, LLC Delaware Biomet Fair Lawn LLC Indiana Biome
February 25, 2022	EX-4.1	Exhibit 4.1 to our Annual Report on Form 10-K for the year ended December 31, 2021 Exhibit 4.1 Description of the Registrant?s Securities Registered Under Section 12 of the Securities Exchange Act of 1934 As of December 31, 2021, Zimmer Biomet Holdings, Inc. (the ?Company,? ?we,? ?our? and ?us? refer solely to Zimmer Biomet Holdings, Inc.) maintained four classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): (1
February 25, 2022	S-3ASR	As filed with the Securities and Exchange Commission on February 25, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 25, 2022 Registration No.
February 22, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Com
February 22, 2022	EX-99.1	INFORMATION STATEMENT ZimVie Inc. Exhibit 99.1 February 15, 2022 Dear Zimmer Biomet Stockholder: We previously announced plans to separate our spine and dental businesses from our core orthopedic businesses. The separation will occur by means of a spin-off of a newly formed company named ZimVie Inc. (?ZimVie?), which will own the assets and liabilities associated with our spine and dental businesses. Zimmer Biomet Holdings, Inc. (
February 10, 2022	SC 13G/A	ZBH / Zimmer Biomet Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Zimmer Biomet Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 98956P102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is
February 7, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Comm
February 7, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Comm
February 7, 2022	EX-99.1	Investor Day February 7, 2022 Exhibit 99.1 Investor Day February 7, 2022 Disclaimer FORWARD-LOOKING STATEMENTS AND NON-GAAP MEASURES Safe Harbor Statement under the Private Litigation Reform Act of 1995 This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies or prospects. We generally use t
February 7, 2022	EX-99.1	345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zi Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces Fourth Quarter and Full-Year 2021 Financial Results ? Fourth quarter net sales of $2.038 billion decreased 2.3% and
February 7, 2022	EX-99.2	Zimmer Biomet Announces Expected Completion Date of March 1, 2022 for Spinoff of ZimVie Exhibit 99.2 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces Expected Completion Date of March 1, 2022 for Spinoff of ZimVie ? ?When-issued? trading of ZimVie common stock expe
February 7, 2022	EX-99.2	ZimVie Hosts Inaugural Investor Day; Provides 2022 Financial Outlook Exhibit 99.2 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Zimmer Biomet Media Zimmer Biomet Investors Meredith Weissman Keri Mattox 703-346-3127 215-275-2431 [email protected] [email protected] Ezgi Yagci 617-549-2443 [email protected] ZimVie Media ZimVie Investors Laura Driscoll Marissa Bych 774-284-1606 805-305-1244 [email protected] m
January 28, 2022	SC 13G	ZBH / Zimmer Biomet Holdings Inc / JPMORGAN CHASE & CO - FILING ZIMMER BIOMET HOLDINGS, INC. Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ZIMMER BIOMET HOLDINGS, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 98956P102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa
November 30, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2021 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction (Commission (IRS Emplo
November 30, 2021	EX-99.2	Zimmer Biomet Announces Pricing of its Tender Offers for Certain Outstanding Debt Securities Exhibit 99.2 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces Pricing of its Tender Offers for Certain Outstanding Debt Securities (WARSAW, IN) November 30, 2021?Zimmer Biomet H
November 30, 2021	EX-99.1	Zimmer Biomet Announces Early Results and Upsize of its Tender Offers for Certain Outstanding Debt Securities Exhibit 99.1 345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Media Investors Meredith Weissman Keri Mattox (703) 346-3127 (215) 275-2431 [email protected] [email protected] Ezgi Yagci (617) 549-2443 [email protected] Zimmer Biomet Announces Early Results and Upsize of its Tender Offers for Certain Outstanding Debt Securities (WARSAW, IN) November 30, 202
November 24, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 24, 2021 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Com
November 24, 2021	S-8	As filed with the Securities and Exchange Commission on November 24, 2021 As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.
November 24, 2021	S-8 POS	As filed with the Securities and Exchange Commission on November 24, 2021 As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.
November 24, 2021	EX-4.2	Eighth Supplemental Indenture, dated as of November 24, 2021, between Zimmer Biomet Holdings, Inc. and Computershare Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.2 to the Registrant’s Current Report on Form 8-K filed November 24, 2021) Exhibit 4.2 EXECUTION VERSION ZIMMER BIOMET HOLDINGS, INC. $850,000,000 1.450% Notes due 2024 $750,000,000 2.600% Notes due 2031 EIGHTH SUPPLEMENTAL INDENTURE Dated as of November 24, 2021 to Indenture dated as of November 17, 2009 COMPUTERSHARE TRUST COMPANY, N.A. Trustee Table of Contents Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE SECTION 1.01. Application of this Eighth Supplemen
November 24, 2021	S-8 POS	As filed with the Securities and Exchange Commission on November 24, 2021 As filed with the Securities and Exchange Commission on November 24, 2021 Registration No.
November 18, 2021	EX-1.1	Underwriting Agreement, dated as of November 15, 2021, among Zimmer Biomet Holdings, Inc., Barclays Capital Inc., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, BNP Paribas Securities Corp. and BofA Securities, Inc. Exhibit 1.1 EXECUTION VERSION $1,600,000,000 Zimmer Biomet Holdings, Inc. $850,000,000 1.450% Notes due 2024 $750,000,000 2.600% Notes due 2031 Underwriting Agreement New York, New York November 15, 2021 Barclays Capital Inc. Citigroup Global Markets Inc. Goldman Sachs & Co. LLC BNP Paribas Securities Corp. BofA Securities, Inc. As representatives of the several underwriters named in Schedule I he
November 18, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 001-16407 13-4151777 (State or other jurisdiction of incorporation) (Com

AT:ZBH
IT:1ZBH	€ 91.00
MX:ZBH
GB:0QQD
DE:ZIM	€ 89.54
CH:ZBH

ZBH / Zimmer Biomet Holdings, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings